Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company ...

Certara ( ($CERT) ) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment ...

Physiomics ( ($GB:PYC) ) has shared an announcement. Physiomics plc announced a new contract with Numab Therapeutics AG to support the ...

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

Simulations Plus, Inc. (NASDAQ: SLP) shares lost ground Thursday. The company, a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will ...